|
|
||||||||
From the Division of Neurology (Drs. Chiò and Mutani), Department of Neuroscience, University of Torino and Azienda Ospedaliera S. Giovanni Battista, Torino; Department of Neurological Rehabilitation (Dr. Mora), Fondazione S. Maugeri, Clinica del Lavoro e della Riabilitazione, IRCCS, Scientific Institute of Veruno; Division of Neurology (Dr. Leone), "A. Avogadro" University and Azienda Ospedaliera Maggiore della Carità, Novara; Department of Neurology (Dr. Mazzini), S. Giovanni Bosco Hospital, Turin; Division of Neurology (Dr. Cocito), Department of Neuroscience, University of Turin; Department of Neuroscience (Dr. Giordana), University of Torino, and Azienda Ospedaliera San Luigi Gonzaga, Orbassano; and Department of Neurology (Dr. Bottacchi), Azienda Sanitaria Locale di Aosta, Italy.
Address correspondence and reprint requests to Dr. Adriano Chiò, Department of Neuroscience, University of Torino, via Cherasco 15, 10126 Torino, Italy; e-mail: achio{at}usa.net
Objective: To define the factors related to ALS outcome in a population-based, prospective survey.
Methods: The 221 patients (120 men and 101 women) listed in the Piemonte and Valle dAosta ALS Register between 1995 and 1996 were enrolled in the study. The patients were prospectively monitored with a standard evaluation form after diagnosis.
Results: Mean age at onset was 62.8 (SD = 11.2) years. According to El Escorial diagnostic criteria (EEDC), 112 patients had definite ALS, 85 probable ALS, 18 possible ALS, and six suspected ALS. The median survival time from symptom onset was 915 days (95% CI = 790 to 1065). The median survival time from diagnosis was 580 days (95% CI = 490 to 670). In univariate analysis, outcome was significantly related to age, onset site, EEDC classification, and symptom progression rate (i.e., the rate of decline of muscle strength and bulbar and respiratory function in the 6 months after diagnosis). In the Cox multivariate model, age, progression rate of respiratory, bulbar, and lower limb symptoms, EEDC classification, percutaneous endoscopic gastrostomy, and treatment with riluzole were significantly related to outcome.
Conclusions: The rate of progression of symptoms in early ALS is predictive of disease outcome.
This article has been cited by other articles:
![]() |
W. T. Hu, H. Seelaar, K. A. Josephs, D. S. Knopman, B. F. Boeve, E. J. Sorenson, L. McCluskey, L. Elman, H. J. Schelhaas, J. E. Parisi, et al. Survival Profiles of Patients With Frontotemporal Dementia and Motor Neuron Disease Arch Neurol, November 1, 2009; 66(11): 1359 - 1364. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. G. Miller, C. E. Jackson, E. J. Kasarskis, J. D. England, D. Forshew, W. Johnston, S. Kalra, J. S. Katz, H. Mitsumoto, J. Rosenfeld, et al. Practice Parameter update: The care of the patient with amyotrophic lateral sclerosis: Drug, nutritional, and respiratory therapies (an evidence-based review): Report of the Quality Standards Subcommittee of the American Academy of Neurology Neurology, October 13, 2009; 73(15): 1218 - 1226. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Zoccolella, E Beghi, G Palagano, A Fraddosio, V Guerra, V Samarelli, V Lepore, I L Simone, P Lamberti, L Serlenga, et al. Analysis of survival and prognostic factors in amyotrophic lateral sclerosis: a population based study J. Neurol. Neurosurg. Psychiatry, January 1, 2008; 79(1): 33 - 37. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Logroscino, E. Beghi, O. Hardiman, A. Chio, J. D. Mitchell, R. J. Swingler, B. Traynor, for EURALS, E. J. Sorenson, J. Mandrekar, et al. EFFECT OF REFERRAL BIAS ON ASSESSING SURVIVAL IN ALS Neurology, August 28, 2007; 69(9): 939 - 940. [Full Text] [PDF] |
||||
![]() |
C. L Shoesmith, K. Findlater, A. Rowe, and M. J Strong Prognosis of amyotrophic lateral sclerosis with respiratory onset J. Neurol. Neurosurg. Psychiatry, June 1, 2007; 78(6): 629 - 631. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. Visser, R. M. van den Berg-Vos, H. Franssen, L. H. van den Berg, J. H. Wokke, J. M. Vianney de Jong, R. Holman, R. J. de Haan, and M. de Visser Disease Course and Prognostic Factors of Progressive Muscular Atrophy Arch Neurol, April 1, 2007; 64(4): 522 - 528. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. C. Tartaglia, A. Rowe, K. Findlater, J. B. Orange, G. Grace, and M. J. Strong Differentiation Between Primary Lateral Sclerosis and Amyotrophic Lateral Sclerosis: Examination of Symptoms and Signs at Disease Onset and During Follow-up Arch Neurol, February 1, 2007; 64(2): 232 - 236. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Czaplinski, L. J. Haverkamp, A. A. Yen, E. P. Simpson, E. C. Lai, and S. H. Appel The value of database controls in pilot or futility studies in ALS Neurology, November 28, 2006; 67(10): 1827 - 1832. [Abstract] [Full Text] [PDF] |
||||
![]() |
S Kalra, A Vitale, N R Cashman, A Genge, and D L Arnold Cerebral degeneration predicts survival in amyotrophic lateral sclerosis J. Neurol. Neurosurg. Psychiatry, November 1, 2006; 77(11): 1253 - 1255. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Chio, E Bottacchi, C Buffa, R Mutani, G Mora, and the PARALS Positive effects of tertiary centres for amyotrophic lateral sclerosis on outcome and use of hospital facilities J. Neurol. Neurosurg. Psychiatry, August 1, 2006; 77(8): 948 - 950. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Czaplinski, A A Yen, and S H Appel Forced vital capacity (FVC) as an indicator of survival and disease progression in an ALS clinic population. J. Neurol. Neurosurg. Psychiatry, March 1, 2006; 77(3): 390 - 392. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Chio, G. Benzi, M. Dossena, R. Mutani, and G. Mora Severely increased risk of amyotrophic lateral sclerosis among Italian professional football players Brain, March 1, 2005; 128(3): 472 - 476. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Kaufmann, G. Levy, J. L.P. Thompson, M. L. DelBene, V. Battista, P. H. Gordon, L. P. Rowland, B. Levin, and H. Mitsumoto The ALSFRSr predicts survival time in an ALS clinic population Neurology, January 11, 2005; 64(1): 38 - 43. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Armon and R. W. Haley Excess incidence of ALS in young Gulf War veterans Neurology, November 23, 2004; 63(10): 1986 - 1987. [Full Text] [PDF] |
||||
![]() |
A. Chio, R. Mutani, G. Mora, W.T. Longstreth Jr., and M.A. del Aguila Prognosis in amyotrophic lateral sclerosis: A population-based study Neurology, December 23, 2003; 61(12): 1826 - 1827. [Full Text] [PDF] |
||||
![]() |
R. W. Haley Excess incidence of ALS in young Gulf War veterans Neurology, September 23, 2003; 61(6): 750 - 756. [Abstract] [Full Text] [PDF] |
||||
![]() |
M R Turner, M J Parton, C E Shaw, P N Leigh, and A Al-Chalabi Prolonged survival in motor neuron disease: a descriptive study of the King's database 1990-2002 J. Neurol. Neurosurg. Psychiatry, July 1, 2003; 74(7): 995 - 997. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Turner, A. Al-Chalabi, A. Chio, and G. Mora Early symptom progression rate is related to ALS outcome: A prospective population-based study Neurology, December 24, 2002; 59(12): 2012 - 2013. [Full Text] [PDF] |
||||
Read all Correspondence
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |